expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.
脾
酪氨酸激酶(Syk)在自身免疫,炎症和肿瘤疾病适应症中是有吸引力的药物靶标。最先进的Syk
抑制剂,R406,1(或它的前药形式fostamatinib,2),已在多个治疗适应症中显示出功效,但其临床进展已经由已被归因,至少部分剂量限制性不利影响的阻碍,到的脱靶活性1。预期选择性更高的Syk
抑制剂将提供更大的治疗窗口。在本文中,我们报告了一系列新型
咪唑并[1,2- a ]
吡嗪Syk
抑制剂的发现和优化。这项工作在GS-9973,鉴定高潮68是一种高度选择性和口服有效的Syk
抑制剂,目前正在针对自身免疫和肿瘤学适应症进行临床评估。